NASDAQ:DXCM DexCom (DXCM) Stock Price, News & Analysis $83.88 -0.65 (-0.77%) Closing price 09/9/2026 04:00 PM EasternExtended Trading$84.20 +0.33 (+0.39%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About DexCom Stock (NASDAQ:DXCM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DexCom alerts:Sign Up Key Stats Today's Range$82.80▼$85.1650-Day Range$70.48▼$92.3452-Week Range$54.11▼$92.59Volume3.95 million shsAverage Volume3.80 million shsMarket Capitalization$31.65 billionP/E Ratio33.15Dividend YieldN/APrice Target$88.71Consensus RatingModerate Buy Company Overview DexCom, Inc. develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing. The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data. Dexcom also offers software and digital services, including Dexcom Clarity for glucose data analysis and Dexcom Follow for sharing information with caregivers and health care providers. The company has also expanded into over-the-counter glucose monitoring with Stelo for eligible adults who do not use insulin. Founded in 1999 and headquartered in San Diego, California, DexCom serves customers through health care providers, distributors, pharmacies, and direct channels in the United States and international markets. Its products are used by people with diabetes, including those who require insulin therapy, as well as certain consumers seeking greater insight into glucose patterns.AI Generated. May Contain Errors. Read More DexCom Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreDXCM MarketRank™: DexCom scored higher than 83% of companies evaluated by MarketBeat, and ranked 73rd out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingModerate Buy Consensus RatingDexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 2 strong buy ratings, 21 buy ratings, 2 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for DexCom is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageDexCom has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about DexCom's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth16.67% Earnings GrowthEarnings for DexCom are expected to grow by 16.67% in the coming year, from $2.64 to $3.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DexCom is 33.15, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.09.Price to Earnings Ratio vs. SectorThe P/E ratio of DexCom is 33.15, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.79.Price to Earnings Growth RatioDexCom has a PEG Ratio of 1.42. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDexCom has a P/B Ratio of 11.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DexCom's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.39% of the float of DexCom has been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 2.94, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DexCom has recently decreased by 5.79%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDexCom does not currently pay a dividend.Dividend GrowthDexCom does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.82 News SentimentDexCom has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for DexCom this week, compared to 10 articles on an average week.Search InterestOnly 6 people have searched for DXCM on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows6 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,950,714.00 in company stock.Percentage Held by Insiders0.28% of the stock of DexCom is held by insiders.Percentage Held by Institutions97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DexCom's insider trading history. Receive DXCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DXCM Stock News HeadlinesDexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeptember 9 at 12:00 PM | seekingalpha.comDexCom Stock: Is DXCM Underperforming the Healthcare Sector?September 8 at 4:16 PM | finance.yahoo.comIt’s not about GreenlandThe petrodollar arrangement that anchored the US dollar for 50 years quietly expired in June 2024. Since then, China has cut its Treasury holdings by 45% from their peak, and BRICS nations offloaded $47 billion of American debt in a single month. The Trump administration has responded with a $12 billion critical minerals stockpile called Project Vault, equity stakes in miners like MP Materials and Lithium Americas, and a push to secure resources from Greenland to Ukraine. Porter Stansberry lays out the full story in a new documentary, including five companies positioned at the chokepoints of what he calls Trump's New Dollar. | Porter & Company (Ad)Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?September 7 at 3:27 PM | prnewswire.comDexCom (NASDAQ:DXCM) Upgraded at Wall Street ZenSeptember 6, 2026 | americanbankingnews.comBrokerages Set DexCom, Inc. (NASDAQ:DXCM) PT at $88.71September 5, 2026 | americanbankingnews.comQ2 earnings highs and lows: DexCom (NASDAQ:DXCM) vs the rest of the patient monitoring stocksSeptember 3, 2026 | msn.comSadie Stern Sells 2,565 Shares of DexCom (NASDAQ:DXCM) StockAugust 29, 2026 | insidertrades.comSee More Headlines DXCM Stock Analysis - Frequently Asked Questions How have DXCM shares performed this year? DexCom's stock was trading at $66.37 at the start of the year. Since then, DXCM shares have increased by 26.4% and is now trading at $83.88. How were DexCom's earnings last quarter? DexCom, Inc. (NASDAQ:DXCM) posted its earnings results on Thursday, July, 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.09. DexCom's revenue for the quarter was up 13.1% compared to the same quarter last year. Read the conference call transcript. When did DexCom's stock split? Shares of DexCom split on Friday, June 10th 2022.The 4-1 split was announced on Friday, March 25th 2022. The newly issued shares were payable to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. Does DexCom have any subsidiaries? The following companies are subsidiaries of DexCom: TypeZero Technologies Inc, Nintamed Handels GmbH, DexCapital LLC, DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom (Canada) Inc., DexCom Deutschland GmbH, and more. Who are DexCom's major shareholders? Top institutional shareholders of DexCom include California State Teachers Retirement System (10.38%), UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (2.98%), Wellington Management Group LLP (2.26%) and Legal & General Group Plc (0.68%). Insiders that own company stock include Jacob Steven Leach, Kevin R Sayer, Jereme M Sylvain, Sadie Stern, Steven Robert Pacelli, Michael Jon Brown, Jon Coleman, Jon Coleman, Barry J Regan, Steven R Altman, Mark G Foletta, Matthew Vincent Dolan, Richard Alexander Collins, Nicholas Augustinos, Bridgette P Heller and Kyle Malady. View institutional ownership trends. How do I buy shares of DexCom? Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DexCom own? Based on aggregate information from My MarketBeat watchlists, some other companies that DexCom investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Invesco QQQ (QQQ). Company Calendar Last Earnings7/30/2026Today9/09/2026Wells Fargo 21st Annual Healthcare Conference9/09/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 DXCM's financial health is in the Green zone, according to TradeSmith. DXCM has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:DXCM CIK1093557 Webwww.dexcom.com Phone(858) 200-0200Fax858-200-0201Employees11,000Year Founded1999Price Target and Rating Average Price Target for DexCom$88.71 High Price Target$105.00 Low Price Target$64.00 Potential Upside/Downside+5.8%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage26 Analysts Profitability EPS (Trailing Twelve Months)$2.53 Trailing P/E Ratio33.15 Forward P/E Ratio31.77 P/E Growth1.42Net Income$836.30 million Net Margins20.12% Pretax Margin25.76% Return on Equity35.94% Return on Assets14.75% Debt Debt-to-Equity Ratio0.47 Current Ratio1.73 Quick Ratio1.43 Sales & Book Value Annual Sales$4.66 billion Price / Sales6.79 Cash Flow$2.75 per share Price / Cash Flow30.53 Book Value$7.04 per share Price / Book11.91Miscellaneous Outstanding Shares377,360,000Free Float376,304,000Market Cap$31.65 billion OptionableOptionable Beta1.42 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:DXCM) was last updated on 9/10/2026 by MarketBeat.com Staff. From Our PartnersWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...Banyan Hill Publishing | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DexCom With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
